R. Unit, O. Centre, and . Lambret, Centre Oscar Lambret, issue.8

S. Sleijfer, C. Seynaeve, and J. Verweij, Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care, Oncologist, vol.10, pp.833-874, 2005.

N. Penel, M. Van-glabbeke, S. Marreaud, M. Ouali, P. Hohenberger et al., Testing new regimes in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years, Ann Oncol, vol.22, pp.1266-72, 2011.

G. D. Demetri, S. P. Chawla, M. Von-mehren, R. P. Baker, L. H. Blay et al., Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules, J Clin Oncol, vol.27, pp.4188-96, 2009.

R. G. Maki, J. K. Wathen, S. R. Patel, D. A. Priebat, S. H. Okuno et al., Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002, J Clin Oncol, vol.25, pp.2755-63, 2007.

S. Sleijfer, I. Ray-coquard, Z. Papai, L. Cesne, A. Scurr et al., Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043), J Clin Oncol, vol.27, pp.3126-3158, 2009.

A. Potti, A. K. Ganti, K. Tendulkar, K. Sholes, S. Chitajallu et al., Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role in leiomyosarcoma, J Cancer Res Clin Oncol, vol.130, pp.52-58, 2004.

E. E. Pakos, A. C. Goussia, P. G. Tsekeris, D. J. Papachristou, D. Stefanou et al., Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas, Anticancer Res, vol.25, pp.3591-3597, 2005.

C. Chao, T. Al-saleem, J. J. Brooks, A. Rogatko, W. G. Kraybill et al., Vascular endothelial growth factor and soft tissue sarcomas: Tumor expression correlated with grade, Ann Surg Oncol, vol.8, pp.260-267, 2001.

K. Yudoh, M. Kanamori, K. Ohmori, T. Yasuda, M. Aoki et al., Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas, Br J Cancer, vol.84, pp.1610-1615, 2001.

U. Graeven, N. Andre, E. Achilles, C. Zornig, and W. Schmiegel, Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with softtissue sarcoma, J Cancer Res Clin Oncol, vol.125, pp.577-81, 1999.

A. J. Hayes, A. Mostyn-jones, M. U. Koban, A. 'hern, R. Burton et al., Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma, Br J Surg, vol.91, pp.242-249, 2004.

S. S. Yoon, N. H. Segal, A. B. Olshen, M. F. Brennan, and S. Singer, Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft-tissue sarcoma, Ann Oncol, vol.15, pp.1261-1267, 2004.

S. S. Yoon, N. H. Segal, P. J. Park, K. Y. Detwiller, N. T. Fernando et al., Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression, J Surg Res, vol.135, pp.282-90, 2006.

. Wt-v-d-g, J. Y. Blay, S. P. Chawal, D. W. Kim, B. Bui-nguyen et al., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind,placebo-controlled phase 3 trial, Lancet, vol.379, pp.1879-86, 2012.

K. Mross, A. Frost, S. Steinbild, S. Hedbom, M. Büchert et al., A phase I dose-escalation study of oral Regorafenib (BAY 73-4506), An Inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors, Clin Cancer Res, vol.18, pp.2658-67, 2012.

S. M. Wilhem, J. Dumas, L. Adnane, M. Lynch, C. A. Carter et al., Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kiases with potent preclinical antitumor activity, Int J Cancer, vol.129, pp.245-55, 2011.

A. Grothey, E. Van-cutsem, A. Sobrero, S. Siena, A. Falcone et al., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial, Lancet, vol.381, pp.303-315, 2013.

G. D. Demetri, P. Reichardt, Y. K. Kang, J. Y. Blay, P. Rutkowski et al., Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, vol.381, pp.295-302, 2013.

S. Cousin, J. Y. Blay, F. Bertucci, N. Isambert, A. Italiano et al., Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group, Ann Oncol, vol.24, pp.2681-2686, 2013.

L. V. Rubinstein, E. L. Korn, B. Freidlin, S. Hunsberger, S. P. Ivy et al., Submit your next manuscript to BioMed Central and take full advantage of: ? Convenient online submission ? Thorough peer review ? No space constraints or color figure charges ? Immediate publication on acceptance ? Inclusion in PubMed, CAS, Scopus and Google Scholar ? Research which is freely available for redistribution, J Clin Oncol, vol.23, pp.7199-206, 2005.